Amphastar Pharmaceuticals (AMPH) Cash & Equivalents (2013 - 2026)

Amphastar Pharmaceuticals' Cash & Equivalents history runs 14 years deep, the most recent figure standing at $170.9 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 6.48% year-over-year to $170.9 million in Q1 2026; TTM through Mar 2026 was $170.9 million, a 6.48% decrease from a year earlier, with the FY2025 full-year figure at $170.2 million, up 12.25% from the prior year.
• Cash & Equivalents was little changed at $170.9 million in Q1 2026 per AMPH's latest filing, from $170.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $266.8 million in Q3 2023 and bottomed at $144.3 million in Q4 2023.
• The 5-year median for Cash & Equivalents is $172.6 million (2022), against an average of $179.5 million.
• Across the five-year window, Cash & Equivalents jumped 69.91% in 2022 and decreased 27.99% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $156.1 million in 2022, then fell by 7.56% to $144.3 million in 2023, then gained by 5.07% to $151.6 million in 2024, then rose by 12.25% to $170.2 million in 2025, then gained by 0.45% to $170.9 million in 2026.
• Per Business Quant, the three latest AMPH Cash & Equivalents figures stand at $170.9 million (Q1 2026), $170.2 million (Q4 2025), and $216.3 million (Q3 2025).